Biotech Values

[daved]

Big Biotechs' answer to biogenerics.

As it turns out the Sangamo/Genentech deal is much bigger than my initial read. It sets a precedent.

Here is a list of some of thecompanies licensing Sangamo technology for protein production:
Amgen
Pfizer
Genentec
Novartis
Novo Nordisk
Medarex
Medimune
Chiron

The difference with Genentec is that they secured a commercial license that comtemplates converting all biologic production to Sangamo derived protein and cell lines. Instead of using the word royalties the agreement spells out multiple commercial "milestones".

The advantage of Sangamo cell or protein lines is uniqueness. They can easily knock out a specific gene or 2 and are very targeted.

This commercial license sets the precedent. Follow-on agreements can be priced higher, at SGMO's option.

Dave